BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9313601)

  • 1. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
    Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
    Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
    Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
    Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
    Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
    Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential properties of mibefradil in hypertension and angina.
    Kobrin I
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
    Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ; van der Sluijs J; van der Vring JA; Daniëls MC; Holwerda KJ; Withagen AJ; Schelling A; Hendriks MG; Zwinderman AH
    J Clin Pharmacol; 1999 Jul; 39(7):738-46. PubMed ID: 10392329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
    Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S; van der Wall EE; Emanuelsson H; Kobrin I
    J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
    Charlon V; Kobrin I
    Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.
    Lee DS; Goodman S; Dean DM; Lenis J; Ma P; Gervais PB; Langer A;
    Am Heart J; 2002 Jul; 144(1):60-7. PubMed ID: 12094189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.